Through flux and fluidity, FDA keeps coming back to rare disease

Summary

FDA approvals for biologic therapies declined in H1 2026, but regulatory experts remain optimistic about rare disease approvals following leadership changes at the agency. The article notes ongoing tension between scientific and political considerations in FDA decision-making.